COVID-19 Information

Edit Entry | Edit CV

Lucas A Salas, MD, MPH, PhD

Title(s)
Assistant Professor of Epidemiology

Additional Titles/Positions/Affiliations
Investigator Cancer Population Sciences Research Program, Dartmouth Hitchcock- Norris Cotton Cancer Center

Department(s)
Epidemiology

Education
Universitat Pompeu Fabra, PhD 2015
Universitat Pompeu Fabra, MPH 2011
Universidad de Antioquia, Epidemiology 2007
Universidad Nacional de Colombia, MD 2001

Programs
Quantitative Biomedical Sciences
Other

NIH Biosketch
Salas_L_BIO_2020-09-21.pdf

Websites
https://sites.dartmouth.edu/salaslab/
https://orcid.org/0000-0002-2279-4097
https://scholar.google.com/citations?user=FsRf5lQAAAAJ&hl=en
https://publons.com/researcher/1222796/lucas-a-salas/
https://bioconductor.org/packages/release/data/experiment/html/FlowSorted.Blood.EPIC.html
https://bioconductor.org/packages/release/data/experiment/html/FlowSorted.CordBloodCombined.450k.html

Contact Information


Professional Interests

The broad goal of Dr. Salas research is to investigate how cell heterogeneity impacts human health and disease, with an emphasis on how genetic, environmental, and lifestyle factors model the human epigenome and therefore the cell plasticity. Dr. Salas’ laboratory studies how some key epigenetic mechanisms (DNA methylation, DNA hydroxymethylation, and miRNA alterations) affect gene expression and cancer outcomes, including how the immune cells are altered in this disease. Other research interests include biomarker development, chronic inflammation, and human disease, and how exposures during fetal life alter newborn and childhood outcomes.

Grant Information

W81XWH-20-1-0778, Congressionally Directed Medical Research Programs/Department of Defense
Salas Diaz, Lucas A (PI) 09/01/20-08/31/24
Epigenetic modifications of cytosines in clear cell kidney carcinogenesis and survival
P20 GM104416-09/8299, National Institute of General Medical Sciences
Salas Diaz, Lucas A (PI) 10/01/20-01/01/23
A single-cell approach to disentangle tumor microenvironments in short and long survivors to clear cell renal carcinoma

Courses Taught

QBS.132
CANB.103
MDED.118
QBS.271
PEMM.212

Mentoring Information

Current trainees:
Ze Zhang, QBS
Steven Pike, IND
Prasoona Karra, Ph.D. (postdoctoral fellow)
David Vargas-Estrella (Neurosciences '23)


Selected Publications

 

HiTIMED: hierarchical tumor immune microenvironment epigenetic deconvolution for accurate cell type resolution in the tumor microenvironment using tumor-type-specific DNA methylation data.
Zhang Z, Wiencke JK, Kelsey KT, Koestler DC, Christensen BC, Salas LA
J Transl Med. 2022 Nov 8;20(1):516. doi: 10.1186/s12967-022-03736-6. Epub 2022 Nov 8.
PMID: 36348337

Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker.
Tang E, Wiencke JK, Warrier G, Hansen H, McCoy L, Rice T, Bracci PM, Wrensch M, Taylor JW, Clarke JL, Koestler DC, Salas LA, Christensen BC, Kelsey KT, Molinaro AM
Clin Epigenetics. 2022 Oct 28;14(1):136. doi: 10.1186/s13148-022-01352-1. Epub 2022 Oct 28.
PMID: 36307860

DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival.
Wiencke JK, Molinaro AM, Warrier G, Rice T, Clarke J, Taylor JW, Wrensch M, Hansen H, McCoy L, Tang E, Tamaki SJ, Tamaki CM, Nissen E, Bracci P, Salas LA, Koestler DC, Christensen BC, Zhang Z, Kelsey KT
Nat Commun. 2022 Sep 20;13(1):5505. doi: 10.1038/s41467-022-33215-x. Epub 2022 Sep 20.
PMID: 36127421

MethylMasteR: A Comparison and Customization of Methylation-Based Copy Number Variation Calling Software in Cancers Harboring Large Scale Chromosomal Deletions.
Mariani MP, Chen JA, Zhang Z, Pike SC, Salas LA
Front Bioinform. 2022;2 pii: 859828. doi: 10.3389/fbinf.2022.859828. Epub 2022 Apr 12.
PMID: 35573871

A Novel Framework for the Identification of Reference DNA Methylation Libraries for Reference-Based Deconvolution of Cellular Mixtures.
Bell-Glenn S, Thompson JA, Salas LA, Koestler DC
Front Bioinform. 2022;2 pii: 835591. doi: 10.3389/fbinf.2022.835591. Epub 2022 Mar 21.
PMID: 35419567

Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
Salas LA, Stewart TG, Mobley BC, Peng C, Liu J, Loganathan SN, Wang J, Ma Y, Berger MS, Absher D, Hu Y, Moots PL, Christensen BC, Clark SW
Cancer Res Commun. 2022 Jan;2(1):1-9. doi: 10.1158/2767-9764.CRC-21-0088.
PMID: 35392283

A core of differentially methylated CpG loci in gMDSCs isolated from neonatal and adult sources.
Berglund-Brown I, Nissen E, Koestler DC, Butler RA, Eliot MN, Padbury JF, Salas LA, Molinaro AM, Christensen BC, Wiencke JK, Kelsey KT
Clin Epigenetics. 2022 Feb 21;14(1):27. doi: 10.1186/s13148-022-01247-1. Epub 2022 Feb 21.
PMID: 35189960

Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling.
Salas LA, Zhang Z, Koestler DC, Butler RA, Hansen HM, Molinaro AM, Wiencke JK, Kelsey KT, Christensen BC
Nat Commun. 2022 Feb 9;13(1):761. doi: 10.1038/s41467-021-27864-7. Epub 2022 Feb 9.
PMID: 35140201

Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes.
Chen JQ, Salas LA, Wiencke JK, Koestler DC, Molinaro AM, Andrew AS, Seigne JD, Karagas MR, Kelsey KT, Christensen BC
Clin Epigenetics. 2022 Jan 21;14(1):14. doi: 10.1186/s13148-022-01234-6. Epub 2022 Jan 21.
PMID: 35063012

Navigating the hydroxymethylome: experimental biases and quality control tools for the tandem bisulfite and oxidative bisulfite Illumina microarrays.
Zhang Z, Lee MK, Perreard L, Kelsey KT, Christensen BC, Salas LA
Epigenomics. 2022 Feb;14(3):139-152. doi: 10.2217/epi-2021-0490. Epub 2022 Jan 14.
PMID: 35029129

View more publications on PubMed